Grifols, S.A. (GRF.MC)
| Previous close | 20.63 |
| Open | 20.64 |
| Bid | 20.52 x 0 |
| Ask | 20.54 x 0 |
| Day's range | 20.38 - 20.81 |
| 52-week range | 19.18 - 26.94 |
| Volume | 745,286 |
| Avg. volume | 813,562 |
| Market cap | 12.062B |
| Beta (5Y monthly) | 0.10 |
| PE ratio (TTM) | 25.00 |
| EPS (TTM) | 0.82 |
| Earnings date | 30 Jul 2021 - 09 Aug 2021 |
| Forward dividend & yield | 0.36 (1.61%) |
| Ex-dividend date | 03 Jun 2021 |
| 1y target est | 25.56 |
- Bloomberg
Grifols Buys Biotest as Creat Pushed to Exit Blood-Plasma Stakes
(Bloomberg) -- Grifols SA agreed to buy Biotest AG for about 1.6 billion euros ($1.9 billion), pouncing after U.S. regulators pushed back on Chinese shareholder Creat Group Corp.’s expansion into the blood-plasma industry.Grifols offered 43 euros for each ordinary share and 37 euros for each preferred share, the Spanish company said Friday. That’s 23% and 4.2% higher than Thursday’s closing prices, respectively. Bloomberg News reported late Thursday that the deal was imminent.Creat’s strategy to
- Reuters
Spain's Grifols to buy rival Biotest for up to $1.9 billion
MADRID (Reuters) -Spanish pharmaceuticals company Grifols proposed a 1.6 billion euro ($1.9 billion) takeover of its German rival Biotest on Friday, in a move to consolidate the plasma-based drug industry. Grifols said it had agreed with Tiancheng International Investment to buy the Hong Kong-based company's controlling stake in Biotest for 1.1 billion euros. The Barcelona-based company agreed to buy 89.88% of Biotest's ordinary shares that carry voting rights, but which represent only 44.54% of the company's capital, and a further 0.54% of capital in preferred shares that do not carry voting rights, from Hong Kong-based Tiancheng.
- Zacks
Moving Average Crossover Alert: Grifols (GRFS)
Grifols (GRFS) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
